Dividends & Income
To screen ETFs by asset class, performance, yield and more, check out the
, korlym sales seemed pretty weak taking in consideration it is a orphan drug indication. Neutral.
Add a reply...
Latest StockTalks »
people get CORT breaking news and analysis by email alert.
Get email alerts on CORT »
Corcept Therapeutics Incorporated
Get latest price
From other sites
Corcept Therapeutics' Korlym Positive in Breast Cancer Study - Analyst Blog
at Zacks.com (May 15, 2015)
Corcept Therapeutics Reports Wider Q1 Loss, Revenue Miss - Analyst Blog
at Zacks.com (May 8, 2015)
Corcept Therapeutics (CORT) Looks Good: Stock Up 83.9% - Tale of the Tape
at Zacks.com (Apr 9, 2015)
Corcept Therapeutics (CORT) Jumps: Stock Rises 14.5% - Tale of the Tape
at Zacks.com (Mar 12, 2015)
Earnings Watch: Updates, advisories and surprises
at MarketWatch.com (May 7, 2014)
Xignite quote data
© 2015 Seeking Alpha